Founder at Stock Spin-off Investing, Stock Spin-Off Investing

Richard Howe

Founder at Stock Spin-off Investing

Stock Spin-Off Investing

Generate attractive returns by taking advantage of inefficiencies in the stock spin-off market.

Stock Spin-offs

Event-Driven

<ul><li>The range of ideas is broad. The smallest market cap is a $15MM Canadian micro-cap that is trading below its net cash, and the largest is an $25BN market cap online travel company that is gobbling up its own shares.</li><li>We have ideas profiled from Poland, Canada, India, Austria, Argentina, Italy, and of course, the United States.</li><li>The report will start with my personal favorite idea and then cover the additional ideas in alphabetical order.</li></ul>

The range of ideas is broad. The smallest market cap is a $15MM Canadian micro-cap that is trading below its net cash, and the largest is an $25BN market cap online travel company that is gobbling up its own shares.We have ideas profiled from Poland, Canada, India, Austria, Argentina, Italy, and of course, the United States.The report will start with my personal favorite idea and then cover the additional ideas in alphabetical order.

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>Takeda is navigating a transitional period, balancing the significant revenue decline from the loss of exclusivity for its ADHD drug Vyvanse with the strong growth of its core products, particularly Entyvio for inflammatory bowel disease.</li>
 <li>The company's long-term growth hinges on its late-stage R&amp;D pipeline, which features several potential blockbuster assets in areas like psoriasis (zasocitinib), narcolepsy (oveprexton/Orzeyful), and rare diseases, collectively estimated to have peak sales potential between $10 billion and $20 billion.</li>
 <li>Strategic focus remains on deleveraging the balance sheet post-Shire acquisition, enhancing R&amp;D productivity, and driving operational efficiencies through a major restructuring program to fund future growth and maintain its commitment to shareholder returns via a strong dividend.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Takeda is navigating a transitional period, balancing the significant revenue decline from the loss of exclusivity for its ADHD drug Vyvanse with the strong growth of its core products, particularly Entyvio for inflammatory bowel disease.
  The company's long-term growth hinges on its late-stage R&amp;D pipeline, which features several potential blockbuster assets in areas like psoriasis (zasocitinib), narcolepsy (oveprexton/Orzeyful), and rare diseases, collectively estimated to have peak sales potential between $10 billion and $20 billion.
  Strategic focus remains on deleveraging the balance sheet post-Shire acquisition, enhancing R&amp;D productivity, and driving operational efficiencies through a major restructuring program to fund future growth and maintain its commitment to shareholder returns via a strong dividend.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Takeda Pharmaceutical (4502 JP) - Aug 2026

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Takeda Pharmaceutical (4502 JP) announced positive topline results for Phase 3 study comparing zasocitinib (TAK-279), an investigational, highly selective oral TYK2 inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis.</li>
<li>Takeda also presented additional results from two pivotal studies, showing oveporexton (TAK-861), an OX2R-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1.</li>
<li>Takeda’s pipeline is positioned to support both the near-term and long-term sustained growth of the company.</li>
</ul>


Takeda Pharmaceutical (4502 JP) announced positive topline results for Phase 3 study comparing zasocitinib (TAK-279), an investigational, highly selective oral TYK2 inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis.
Takeda also presented additional results from two pivotal studies, showing oveporexton (TAK-861), an OX2R-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1.
Takeda’s pipeline is positioned to support both the near-term and long-term sustained growth of the company.


Takeda Pharmaceutical: Zasocitinib, Oveprexton Positive Results Shows Takeda’s Pipeline Strength

Derivatives and Quantitative Strategist

Gaudenz Schneider

Quantitative Analysis

<ul>
<li>
Context: A recent market pullback alongside implied volatility at the 95th–98th percentile has created a fertile environment for cross-sectional analysis across TOPIX and Nikkei 225 constituents.</li>
<li>
 Highlights: A quantitative screen reveals dispersion in both returns and volatility, with distinct clusters supporting different option structures—from premium-selling strategies to asymmetric upside participation.</li>
<li>
 Why read: This note provides a practical framework and illustrative setups (put underwriting, risk reversals) to help investors translate volatility signals into tailored option strategies.</li>
</ul>



Context: A recent market pullback alongside implied volatility at the 95th–98th percentile has created a fertile environment for cross-sectional analysis across TOPIX and Nikkei 225 constituents.

 Highlights: A quantitative screen reveals dispersion in both returns and volatility, with distinct clusters supporting different option structures—from premium-selling strategies to asymmetric upside participation.

 Why read: This note provides a practical framework and illustrative setups (put underwriting, risk reversals) to help investors translate volatility signals into tailored option strategies.


Japan Equities: Volatility Spike and Dispersion Create Options Opportunities

Japan

Takeda Pharmaceutical Co Ltd focuses on the Research & Development, Manufacturing, Sales and Marketing and Import/Export of Pharmaceutical Drugs. The Company focuses on the following core therapeutic areas: Cardiovascular & Metabolic, Oncology, Central Nervous System, Respiratory & Immunology, General Medicine (Gastrointestinal & Genitourinary) and Vaccine.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Takeda Pharmaceutical (4502 JP)

Best Ideas of 2025

The range of ideas is broad. The smallest market cap is a $15MM Canadian micro-cap that is trading below its net cash, and the largest is an $25BN...

Richard Howe

Primer: Takeda Pharmaceutical (4502 JP) - Aug 2026

Takeda is navigating a transitional period, balancing the significant revenue decline from the loss of exclusivity for its ADHD drug Vyvanse...

αSK Primers

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Takeda Pharmaceutical: Zasocitinib, Oveprexton Positive Results Shows Takeda’s Pipeline Strength

Takeda Pharmaceutical reports positive Phase 3 results for zasocitinib and oveporexton, showcasing potential for sustained growth and pipeline...

Tina Banerjee

Japan Equities: Volatility Spike and Dispersion Create Options Opportunities

This note presents a cross-sectional approach to identifying options strategies in Japanese equities, set against a backdrop of market pullback and...

Gaudenz Schneider

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Best Ideas of 2025

The range of ideas is broad. The smallest market cap is a $15MM Canadian micro-cap that is trading below its net cash, and the largest is an $25BN...

Richard Howe

Primer: Takeda Pharmaceutical (4502 JP) - Aug 2026

Takeda is navigating a transitional period, balancing the significant revenue decline from the loss of exclusivity for its ADHD drug Vyvanse...

αSK Primers

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Takeda Pharmaceutical: Zasocitinib, Oveprexton Positive Results Shows Takeda’s Pipeline Strength

​Takeda Pharmaceutical reports positive Phase 3 results for zasocitinib and oveporexton, showcasing potential for sustained growth and pipeline...

Tina Banerjee

Japan Equities: Volatility Spike and Dispersion Create Options Opportunities

This note presents a cross-sectional approach to identifying options strategies in Japanese equities, set against a backdrop of market pullback and...

Gaudenz Schneider

Takeda Pharmaceutical reports positive Phase 3 results for zasocitinib and oveporexton, showcasing potential for sustained growth and pipeline...